This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giannasca, P. J.
Right arrow Articles by Thomas, W. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giannasca, P. J.
Right arrow Articles by Thomas, W. D., Jr.

 Previous Article  |  Next Article 

Infection and Immunity, February 1999, p. 527-538, Vol. 67, No. 2
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Serum Antitoxin Antibodies Mediate Systemic and Mucosal Protection from Clostridium difficile Disease in Hamsters

Paul J. Giannasca,* Zhen-xi Zhang, Wen-de Lei, James A. Boden, Mary Ann Giel, Thomas P. Monath, and William D. Thomas Jr.

OraVax, Inc., Cambridge, Massachusetts 02139

Received 21 August 1998/Returned for modification 25 September 1998/Accepted 4 November 1998

Clostridium difficile is the bacterial pathogen identified as the cause of pseudomembranous colitis and is principally responsible for nosocomial antibiotic-associated diarrhea and colitis. The pathologic findings associated with this infection are believed to be caused by two large (~300-kDa) exotoxins, toxins A and B. Because of the mucosal nature of this infection, vaccination strategies aimed at providing prophylactic or therapeutic immune protection have included immunization by mucosal routes. Using the hamster model of C. difficile infection, we examined the protective efficacy of inactivated toxin (toxoid) vaccine formulations prepared as either culture filtrate or partially purified toxoid. We compared combination parenteral and mucosal vaccination regimens involving intranasal, intragastric, or rectal routes of immunization and found that rectal immunization in conjunction with intramuscular (i.m.) vaccination provided full protection of hamsters from death and diarrhea while the other mucosal routes did not. Protection was associated with high levels of toxin-neutralizing antibodies in serum. The requirement for adjuvants for protection was assessed by using sequential i.m. and rectal or i.m. vaccination regimens. Unexpectedly, i.m. immunization without adjuvant conferred the highest protection from death and diarrhea; this regimen elicited the highest serum anti-toxin B titers as well as toxin B neutralizing titers. Passive transfer of mouse antitoxin antibodies protected hamsters in a dose-dependent manner, demonstrating the principal role of circulating antitoxin antibodies in immunity from this toxin-mediated mucosal disease. These results suggest that prophylactic parenteral vaccination or intravenous immunotherapy could provide protection from C. difficile disease in humans.


* Corresponding author. Mailing address: OraVax, Inc., 38 Sidney St., Cambridge, MA 02139. Phone: (617) 494-1339. Fax: (617) 494-0927. E-mail: pgiannas{at}oravax.com.


Infection and Immunity, February 1999, p. 527-538, Vol. 67, No. 2
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Ghose, C., Kalsy, A., Sheikh, A., Rollenhagen, J., John, M., Young, J., Rollins, S. M., Qadri, F., Calderwood, S. B., Kelly, C. P., Ryan, E. T. (2007). Transcutaneous Immunization with Clostridium difficile Toxoid A Induces Systemic and Mucosal Immune Responses and Toxin A-Neutralizing Antibodies in Mice. Infect. Immun. 75: 2826-2832 [Abstract] [Full Text]  
  • Babcock, G. J., Broering, T. J., Hernandez, H. J., Mandell, R. B., Donahue, K., Boatright, N., Stack, A. M., Lowy, I., Graziano, R., Molrine, D., Ambrosino, D. M., Thomas, W. D. Jr. (2006). Human Monoclonal Antibodies Directed against Toxins A and B Prevent Clostridium difficile-Induced Mortality in Hamsters. Infect. Immun. 74: 6339-6347 [Abstract] [Full Text]  
  • Castagliuolo, I., Sardina, M., Brun, P., DeRos, C., Mastrotto, C., Lovato, L., Palu, G. (2004). Clostridium difficile Toxin A Carboxyl-Terminus Peptide Lacking ADP-Ribosyltransferase Activity Acts as a Mucosal Adjuvant. Infect. Immun. 72: 2827-2836 [Abstract] [Full Text]  
  • Mylonakis, E., Ryan, E. T., Calderwood, S. B. (2001). Clostridium difficile-Associated Diarrhea: A Review. Arch Intern Med 161: 525-533 [Abstract] [Full Text]  
  • Kotloff, K. L., Wasserman, S. S., Losonsky, G. A., Thomas, W. Jr., Nichols, R., Edelman, R., Bridwell, M., Monath, T. P. (2001). Safety and Immunogenicity of Increasing Doses of a Clostridium difficile Toxoid Vaccine Administered to Healthy Adults. Infect. Immun. 69: 988-995 [Abstract] [Full Text]  
  • Pavliakova, D., Moncrief, J. S., Lyerly, D. M., Schiffman, G., Bryla, D. A., Robbins, J. B., Schneerson, R. (2000). Clostridium difficile Recombinant Toxin A Repeating Units as a Carrier Protein for Conjugate Vaccines: Studies of Pneumococcal Type 14, Escherichia coli K1, and Shigella flexneri Type 2a Polysaccharides in Mice. Infect. Immun. 68: 2161-2166 [Abstract] [Full Text]  
  • Stubbe, H., Berdoz, J., Kraehenbuhl, J.-P., Corthesy, B. (2000). Polymeric IgA Is Superior to Monomeric IgA and IgG Carrying the Same Variable Domain in Preventing Clostridium difficile Toxin A Damaging of T84 Monolayers. J. Immunol. 164: 1952-1960 [Abstract] [Full Text]  
  • Ward, S. J., Douce, G., Dougan, G., Wren, B. W. (1999). Local and Systemic Neutralizing Antibody Responses Induced by Intranasal Immunization with the Nontoxic Binding Domain of Toxin A from Clostridium difficile. Infect. Immun. 67: 5124-5132 [Abstract] [Full Text]